Answers are grounded in this paper and cite their sources.
This patent review highlights the growth of BTK inhibitors in B-cell malignancies and autoimmune diseases, suggesting their promising therapeutic potential.
Introduction Bruton's tyrosine kinase (BTK) is a critical regulator in the pathogenesis of B-cell malignancies, inflammatory diseases, and autoimmune diseases. In recent years, BTK inhibitors have been a hot topic in drug development, with promising therapeutic prospects. Six BTK inhibitors have been approved, and several (including PROTAC) are undergoing clinical research.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: